Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADAG NASDAQ:DTIL NASDAQ:IZTC NASDAQ:SLGL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADAGAdagene$4.47$3.75$1.30▼$4.85$211.82M0.58283,281 shs81,655 shsDTILPrecision BioSciences$8.18$7.13$3.53▼$8.82$211.06M1.25523,663 shs600,930 shsIZTCInvizyne Technologies$8.48-0.2%$9.03$8.50▼$23.00$53.02MN/A37,647 shs51,030 shsSLGLSol-Gel Technologies$74.01$72.79$6.96▼$97.97$207.96M1.1230,087 shs28,667 shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADAGAdagene0.00%+6.68%+24.86%+12.03%+130.41%DTILPrecision BioSciences0.00%+12.21%+27.61%+40.55%+92.02%IZTCInvizyne Technologies0.00%+5.60%-10.36%-2.97%-13.03%SLGLSol-Gel Technologies0.00%+0.69%-0.48%-6.86%+915.92%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADAGAdagene$4.47$3.75$1.30▼$4.85$211.82M0.58283,281 shs81,655 shsDTILPrecision BioSciences$8.18$7.13$3.53▼$8.82$211.06M1.25523,663 shs600,930 shsIZTCInvizyne Technologies$8.48-0.2%$9.03$8.50▼$23.00$53.02MN/A37,647 shs51,030 shsSLGLSol-Gel Technologies$74.01$72.79$6.96▼$97.97$207.96M1.1230,087 shs28,667 shs7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADAGAdagene0.00%+6.68%+24.86%+12.03%+130.41%DTILPrecision BioSciences0.00%+12.21%+27.61%+40.55%+92.02%IZTCInvizyne Technologies0.00%+5.60%-10.36%-2.97%-13.03%SLGLSol-Gel Technologies0.00%+0.69%-0.48%-6.86%+915.92%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADAGAdagene 3.00Buy$8.0078.97% UpsideDTILPrecision BioSciences 2.60Moderate Buy$32.25294.25% UpsideIZTCInvizyne Technologies 0.00N/AN/AN/ASLGLSol-Gel Technologies 2.67Moderate Buy$197.50166.86% UpsideCurrent Analyst Ratings BreakdownLatest IZTC, ADAG, DTIL, and SLGL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2026SLGLSol-Gel Technologies MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$285.006/9/2026DTILPrecision BioSciences OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$20.006/4/2026SLGLSol-Gel Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D+) ➝ Sell (D-)5/29/2026SLGLSol-Gel Technologies TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy5/27/2026DTILPrecision BioSciences HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$60.005/22/2026SLGLSol-Gel Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Sell (D+)5/15/2026SLGLSol-Gel Technologies Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/11/2026SLGLSol-Gel Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C-) ➝ Hold (C)5/8/2026DTILPrecision BioSciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/24/2026SLGLSol-Gel Technologies Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Hold (C-)4/20/2026ADAGAdagene Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 7/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADAGAdagene$7.67M27.62N/AN/A$0.75 per share5.96DTILPrecision BioSciences$34.26M6.16N/AN/A$4.03 per share2.03IZTCInvizyne TechnologiesN/AN/AN/AN/AN/AN/ASLGLSol-Gel Technologies$18.47M11.26N/AN/A$8.19 per share9.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADAGAdagene-$17.61MN/AN/AN/AN/AN/AN/AN/A9/2/2026 (Estimated)DTILPrecision BioSciences-$45.72M-$3.67N/AN/AN/A-96.73%-85.37%-37.34%8/6/2026 (Estimated)IZTCInvizyne TechnologiesN/AN/AN/AN/AN/AN/AN/AN/AN/ASLGLSol-Gel Technologies-$6.13M-$0.34N/AN/AN/A-5.66%-3.17%-2.58%8/21/2026 (Estimated)Latest IZTC, ADAG, DTIL, and SLGL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/28/2026Q1 2026SLGLSol-Gel Technologies-$2.86-$1.31+$1.55$1.31$0.90 million$0.11 million5/5/2026Q1 2026DTILPrecision BioSciences-$0.6550-$0.75-$0.0950-$0.75$4.05 million$10.84 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthADAGAdageneN/AN/AN/AN/AN/ADTILPrecision BioSciencesN/AN/AN/AN/AN/AIZTCInvizyne TechnologiesN/AN/AN/AN/AN/ASLGLSol-Gel TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADAGAdagene0.033.073.07DTILPrecision BioSciences0.2914.0214.02IZTCInvizyne TechnologiesN/AN/AN/ASLGLSol-Gel TechnologiesN/A8.848.84Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADAGAdagene9.51%DTILPrecision BioSciences37.99%IZTCInvizyne TechnologiesN/ASLGLSol-Gel Technologies26.18%Insider OwnershipCompanyInsider OwnershipADAGAdagene21.20%DTILPrecision BioSciences2.70%IZTCInvizyne TechnologiesN/ASLGLSol-Gel Technologies66.51%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADAGAdagene26047.39 million37.34 millionNot OptionableDTILPrecision BioSciences20025.80 million25.11 millionNo DataIZTCInvizyne Technologies296.25 millionN/AN/ASLGLSol-Gel Technologies502.81 million941,000No DataIZTC, ADAG, DTIL, and SLGL HeadlinesRecent News About These CompaniesInsider Buying: Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Acquires $100,758.00 in StockJuly 5 at 4:53 AM | americanbankingnews.comSol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Acquires $22,460.88 in StockJuly 3 at 6:52 AM | insidertrades.comSol-Gel Technologies (SLGL) Initiated with a Buy at Mizuho SecuritiesJune 26, 2026 | theglobeandmail.comSol-Gel Extends Patidegib IP to 2044 and Bolsters Cash Runway With $33.1 Million OfferingMay 30, 2026 | theglobeandmail.comSol-Gel Technologies Ltd. (SLGL) Reports Q1 Loss, Lags Revenue EstimatesMay 28, 2026 | zacks.comSol-Gel Reports First Quarter 2026 Financial Results and Provides Corporate UpdatesMay 28, 2026 | globenewswire.comInsider Buying: Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Acquires 1,500 Shares of StockMay 15, 2026 | insidertrades.comSol-Gel Technologies Ltd. Announces Pricing of $33.1 Million Underwritten Offering of Ordinary SharesMarch 23, 2026 | quiverquant.comQSol-Gel Technologies Ltd. Announces Pricing of Oversubscribed Underwritten OfferingMarch 23, 2026 | globenewswire.comSol-Gel Technologies Ltd. (SLGL) Reports Q4 Loss, Misses Revenue EstimatesMarch 19, 2026 | zacks.comSol-Gel Files Annual Report on Form 20-F for the Year Ended December 31, 2025March 19, 2026 | globenewswire.comThis Under-the-Radar Stock Has Surged 1,300% Over the Past YearMarch 13, 2026 | finance.yahoo.comSol-Gel Technologies (NASDAQ:SLGL) shareholders have earned a 940% return over the last yearFebruary 11, 2026 | finance.yahoo.comSol-Gel Technologies (SLGL) price target increased by 120.00% to 112.20February 4, 2026 | msn.comOpaleye Management Inc. Buys 1,151 Shares of Sol-Gel Technologies (NASDAQ:SLGL) StockJanuary 24, 2026 | insidertrades.comSol-Gel Technologies: Downgrading To 'Hold' As Success Relies On Upcoming Q4 CatalystJanuary 18, 2026 | seekingalpha.comSol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Opaleye Management Inc. Acquires 8,638 SharesJanuary 1, 2026 | insidertrades.comInsider Buying: Sol-Gel Technologies (NASDAQ:SLGL) Major Shareholder Purchases $10,831.60 in StockDecember 30, 2025 | insidertrades.comWe Think Sol-Gel Technologies (NASDAQ:SLGL) Can Easily Afford To Drive Business GrowthDecember 29, 2025 | finance.yahoo.comWhy Sol-Gel Technologies Ltd.’s (SLGL) Stock Is Down 5.05%December 27, 2025 | aaii.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeIZTC, ADAG, DTIL, and SLGL Company DescriptionsAdagene NASDAQ:ADAG$4.47 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$4.48 +0.01 (+0.22%) As of 07/2/2026 05:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a masked fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase 1b/2 clinical development for the treatment of advanced/metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a v POWERbody, which is in preclinical stage for the treatment off-tumor toxicities, as well as develops anti-CD28 bispecific POWERbody TCEs. The company was incorporated in 2011 and is headquartered in Suzhou, China.Precision BioSciences NASDAQ:DTIL$8.18 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$8.18 0.00 (-0.06%) As of 07/2/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.Invizyne Technologies NASDAQ:IZTC$8.48 -0.02 (-0.24%) As of 07/2/2026Invizyne Technologies Inc. is a cell-free enzyme-based biomanufacturing technology company. It redefining biomanufacturing by leveraging cell-free, multi-step, enzyme-based systems to efficiently transform natural or renewable resources into highly sought after biochemicals. Invizyne Technologies Inc. is based in Monrovia, CA.Sol-Gel Technologies NASDAQ:SLGL$74.01 0.00 (0.00%) Closing price 07/2/2026 04:00 PM EasternExtended Trading$74.32 +0.31 (+0.43%) As of 07/2/2026 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/29 - 07/03 Why Flywire and Airbnb Could Be Quiet Winners of a Ceasefire Meta’s AI Compute Push Could Turn Its Massive CapEx Bill Into a Competitive Weapon Klarna’s Google Court Win Could Give Its BNPL Story a Needed Cash Catalyst This Under-the-Radar Industrial Is Quietly Powering AI SanDisk’s Volatility May Be Telling Bulls What They Want to Hear Broadcom and OpenAI Unveil Jalapeño: An Early Step to Massive AI Growth Potential Why the Comcast Spin-Off Won't Fix What's Actually Broken Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
